Commercial Vehicles

World

Iran Escalates Diplomatic Row, Summons EU Envoys Over Revolutionary Guard's Terror Listing

Iran has summoned the ambassadors of all European Union member states in Tehran in a sharp diplomatic protest against the bloc's recent decision to designate the Islamic Revolutionary Guard Corps (IRGC) as a terrorist organization. The move, triggered by the IRGC's alleged role in suppressing protests, deepens Iran's isolation amid heightened regional tensions.

Feb 2, 2026

World

Rafah Crossing Reopens Under Fragile Truce, Offering Glimmer of Hope for Gaza

The Rafah border crossing between Gaza and Egypt reopened Monday for strictly limited passenger traffic, marking a critical, if symbolic, step in implementing the U.S.-brokered ceasefire. The move follows intense diplomatic efforts and comes as the agreement enters a more complex second phase.

Feb 2, 2026

US

FAA Chief Takes Responsibility for Systemic Failures in Fatal Helicopter Collision

At a Singapore aviation conference, FAA Administrator Bryan Bedford publicly accepted the NTSB's findings that agency failures contributed to a mid-air collision that claimed 67 lives, vowing to implement safety reforms.

Feb 2, 2026

Business

RATIONAL AG Shares Surge 12%: Is the Kitchen Equipment Giant Still a Buy at €678?

RATIONAL AG's stock has seen a notable 12% climb on the XTRA exchange in recent months, reigniting investor debate. Our analysis suggests the shares may now be overvalued, trading above intrinsic value. We examine the outlook, growth potential, and whether investors should wait for a better entry point.

Feb 2, 2026

Business

TransDigm's Billion-Dollar Bet: Do Stellant and Jet Parts Deals Reinforce or Risk Its Aerospace Dominance?

TransDigm Group's recent acquisitions of Stellant Systems and Jet Parts Engineering, totaling over $3 billion, have analysts debating whether the moves solidify its lucrative aftermarket strategy or stretch its leveraged balance sheet too thin ahead of a critical earnings season.

Feb 2, 2026

Business

Exelixis Stock: A Biotech Winner's Valuation Puzzle After Years of Stellar Gains

Exelixis shares have delivered impressive multi-year returns, but recent price weakness has investors questioning if the rally has run its course. A deep dive into valuation models suggests the stock may still be significantly undervalued, presenting a potential opportunity amidst market uncertainty.

Feb 2, 2026

Business

Palantir Cements AI Ambitions with Major Korean Industrial Deal and European Sovereign AI Infrastructure Project

Palantir Technologies expands its strategic footprint in Asia through a deepened partnership with HD Hyundai, while securing a pivotal role in building sovereign AI data centers across Europe, the Middle East, and Africa with Sovereign AI and Accenture.

Feb 2, 2026

Business

Quantum Leap South: D-Wave Relocates HQ from Silicon Valley to Florida, Fueling Tech Exodus Debate

D-Wave Quantum Inc. announces the relocation of its headquarters and core R&D from Palo Alto, California, to Boca Raton, Florida, citing the state's business climate and partnership opportunities, in a move emblematic of a wider coastal tech migration.

Feb 2, 2026

Business

Emma Bridgewater Sees Path to Profitability as Recovery Plan Gains Traction

The iconic pottery maker reports encouraging sales growth and a renewed focus on its craft heritage, aiming to return to profitability next year after a period of job cuts and industry-wide challenges.

Feb 2, 2026

Business

iRhythm Completes Corporate Overhaul, Establishes New Holding Company Structure

Cardiac monitoring specialist iRhythm has finalized a significant corporate restructuring, creating a new parent company to serve as its publicly listed entity on Nasdaq. The move is seen as a strategic step to streamline governance and provide operational flexibility as the company expands its AI-driven health platform.

Feb 2, 2026

Sanofi's Genetic Disorder Drug Shows Promise in Gaucher Trial, Stumbles in Fabry Study

Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.

Feb 2, 2026

Business

Capgemini Divests U.S. Unit Amid Scrutiny Over ICE Software Contract

French IT giant Capgemini moves to sell its U.S. government solutions subsidiary following political and internal pressure over its contract with Immigration and Customs Enforcement (ICE), as public debate intensifies around tech's role in immigration enforcement.

Feb 2, 2026

Business

Insider Bets Signal Hidden Gems: Three European Small-Caps Poised for a Rebound

Amidst a patchy economic recovery, European small-cap stocks are back in focus. A surge in insider buying activity points to potential undervaluation in select names across property, cybersecurity, and defense tech sectors.

Feb 2, 2026

Business

Allegion's Stock Momentum: Is There Still Room to Run After a 26% Surge?

Shares of security products giant Allegion have gained significant momentum, delivering a 26% total return over the past year. With the stock now trading near $165, we examine whether its current valuation still offers an attractive entry point or if future growth is already priced in.

Feb 2, 2026

Business

Takeda's Stock Surge Puts Valuation in Spotlight: Is the Pharma Giant Overpriced or Undervalued?

Takeda Pharmaceutical's (TSE:4502) recent share price rally has ignited a debate among investors. With the stock closing at ¥5,242, analysts are divided on its true worth, presenting a complex picture of fair value signals and future growth prospects.

Feb 2, 2026

Business

Virgin Galactic's Rocky Ascent: Can the Space Tourism Pioneer Overcome Losses and Regain Investor Trust?

As Virgin Galactic's stock hovers near historic lows, the market is grappling with a critical question: Is the pioneering space tourism company a deeply undervalued opportunity, or a speculative bet burdened by persistent losses and ambitious, yet unproven, timelines?

Feb 2, 2026

Business

Bargain Hunt in Asia: Three Undervalued Stocks Poised for Growth in February 2026

Amidst a complex global economic backdrop, Asia's equity markets are hiding gems trading significantly below their estimated intrinsic value. We spotlight three companies—from gaming to aviation and medtech—that our cash flow analysis suggests are deeply discounted, offering potential for investors with an eye on long-term fundamentals.

Feb 2, 2026

Business

IDEAYA Biosciences: A Buying Opportunity After the Pullback, or Priced for Perfection?

IDEAYA Biosciences shares have retreated from recent highs, presenting investors with a dilemma. While long-term performance remains strong, its premium valuation and significant net losses raise questions about whether the current price already reflects its promising pipeline.

Feb 2, 2026

Business

Li Auto Shifts Gears: From Self-Driving Cars to Humanoid Robots in Major AI Pivot

Chinese EV maker Li Auto announces a significant organizational overhaul, dissolving its dedicated autonomous driving team to focus resources on 'embodied intelligence' and humanoid robotics, signaling a bold strategic realignment.

Feb 2, 2026

Business

Kalmar Oyj's 38% Surge: Is the Finnish Port Machinery Giant Still a Buy?

Shares of Kalmar Oyj have soared nearly 40% over the past year, outpacing broader market sentiment. As the stock consolidates near €43, investors are questioning whether the rally still has legs or if the easy money has been made. A deep dive into valuation metrics suggests there may be more room to run.

Feb 2, 2026